Dana-Farber Cancer Institute shared a post on LinkedIn:
“We are proud to announce that both our adult and pediatric stem cell/bone marrow transplant programs have achieved a +1 score in the 2024 Center for International Blood and Marrow Transplant Research (CIBMTR) Transplant Center-Specific Survival Report!
This prestigious score, the highest possible, signifies that our programs have surpassed the expected one-year survival rate for allogeneic or donor stem cell transplants in the U.S.
This marks the fifth consecutive year that Dana-Farber Brigham Cancer Center’s adult stem cell transplant program has earned a +1 score. Notably, among large centers performing over 500 transplants in a three-year period, ours is the only large-volume center to achieve this distinction.
The CIBMTR report analyzed 24,339 allogeneic stem cell/bone marrow transplants across 172 U.S. centers. Our adult and pediatric programs are two of only 12 centers (7%) nationwide, and the only programs in New England and New York, to exceed the expected one-year survival rate for donor stem cell transplants.
Thank you to our dedicated team and partners for their unwavering commitment to excellence and patient care. Together, we continue to make a difference for our patients.”
More posts featuring Dana-Farber Cancer Institute.